Bernard Feigenbaum, MD
The NYU Adverse Drug Reaction and Desensitization Program provides a comprehensive approach to the evaluation and treatment of patients with suspected Adverse Drug Reactions. Depending on the medication and suspected reaction, treatment options may include skin testing, acute drug desensitization, drug challenge and/or test dosing.
For example, acute drug desensitization is a procedure which may allow a patient to tolerate a drug to which they were previously allergic. During this procedure, smaller than usual doses of a drug are administered and the dose is increased in a controlled fashion, under medical supervision and typically according to published protocols.
The Program evaluates Adverse Drug Reactions to drugs such as:
- Antibiotics and other drugs for Infectious Diseases
- Aspirin/NSAIDs (non-steroidal anti-inflammatory medications) such as ibuprofen and naproxen. This includes both IgE-mediated reactions as well as COX-1 inhibition-mediated reactions in patients with Aspirin Exacerbated Respiratory Disease (AERD.)
- Plavix and other blood thinners
- Local anesthetics, such as lidocaine and bupivicaine
- Chemotherapy, such as carboplatin, cisplatin and Taxotere
- Radio-contrast media, commonly known as “x-ray dye”
- Drugs used for In-vitro fertilization (IVF) and other fertility issues, inflammatory bowel disease, rheumatic disease and many other conditions
Dr. Bernard A. Feigenbaum FACP, FAAAAI
Allergy, Asthma & Immunology
Clinical Assistant Professor of Medicine and Otolaryngology
NYU Langone Medical Center 530 First Avenue--Faculty Practice 4G
New York NY 10016
(212) 263-0450
